Sanofi Acquires Q32 Bio Inc.

TL;DR

Sanofi just bought Q32 Bio, taking it private. Nasdaq delisting incoming.

AI Summary

Q32 Bio Inc. announced on March 25, 2024, the completion of its acquisition by a subsidiary of Sanofi. The transaction was approved by Q32 Bio's stockholders on March 22, 2024. As a result of the acquisition, Q32 Bio will cease to be a publicly traded company, and its common stock will no longer be listed on the Nasdaq Capital Market.

Why It Matters

This acquisition by a major pharmaceutical company like Sanofi could lead to accelerated development and potential commercialization of Q32 Bio's pipeline assets, impacting the availability of new treatments.

Risk Assessment

Risk Level: medium — The acquisition itself is a significant event, and the integration of Q32 Bio's assets into Sanofi's operations carries inherent risks.

Key Players & Entities

• Q32 Bio Inc. (company) — Company filing the 8-K
• Sanofi (company) — Acquiring company
• Nasdaq Capital Market (company) — Stock exchange where Q32 Bio was listed

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share QTTB The Nasdaq Capital M
• $1.1989 — ck at a purchase price of approximately $1.1989 per share, for an aggregate purchase pr
• $42.0 million — gregate purchase price of approximately $42.0 million. We refer to this as the pre-closing fi

Filing Documents

• d811189d8k.htm (8-K) — 183KB
• d811189dex31.htm (EX-3.1) — 9KB
• d811189dex32.htm (EX-3.2) — 4KB
• d811189dex101.htm (EX-10.1) — 103KB
• d811189dex102.htm (EX-10.2) — 74KB
• d811189dex103.htm (EX-10.3) — 35KB
• d811189dex104.htm (EX-10.4) — 149KB
• d811189dex105.htm (EX-10.5) — 29KB
• d811189dex106.htm (EX-10.6) — 74KB
• d811189dex107.htm (EX-10.7) — 75KB
• d811189dex108.htm (EX-10.8) — 221KB
• d811189dex109.htm (EX-10.9) — 249KB
• d811189dex1010.htm (EX-10.10) — 41KB
• d811189dex1011.htm (EX-10.11) — 16KB
• d811189dex1012.htm (EX-10.12) — 15KB
• d811189dex1013.htm (EX-10.13) — 63KB
• d811189dex1014.htm (EX-10.14) — 65KB
• d811189dex1015.htm (EX-10.15) — 68KB
• d811189dex1016.htm (EX-10.16) — 68KB
• d811189dex1017.htm (EX-10.17) — 68KB
• d811189dex1018.htm (EX-10.18) — 70KB
• d811189dex161.htm (EX-16.1) — 3KB
• d811189dex231.htm (EX-23.1) — 4KB
• d811189dex991.htm (EX-99.1) — 17KB
• d811189dex992.htm (EX-99.2) — 368KB
• d811189dex993.htm (EX-99.3) — 233KB
• d811189dex994.htm (EX-99.4) — 156KB
• d811189dex995.htm (EX-99.5) — 442KB
• d811189dex996.htm (EX-99.6) — 262KB
• g811189g0325093156698.jpg (GRAPHIC) — 17KB
• g811189g0325093156851.jpg (GRAPHIC) — 25KB
• g811189g0325093157025.jpg (GRAPHIC) — 28KB
• g811189g0325093157184.jpg (GRAPHIC) — 22KB
• g811189g0325093157335.jpg (GRAPHIC) — 15KB
• g811189g0325093157480.jpg (GRAPHIC) — 14KB
• g811189g0325093157747.jpg (GRAPHIC) — 19KB
• g811189g0325093158003.jpg (GRAPHIC) — 17KB
• g811189g0325093158157.jpg (GRAPHIC) — 15KB
• g811189g0325223624242.jpg (GRAPHIC) — 3KB
• 0001193125-24-077930.txt ( ) — 4318KB
• qttb-20240325.xsd (EX-101.SCH) — 3KB
• qttb-20240325_def.xml (EX-101.DEF) — 13KB
• qttb-20240325_lab.xml (EX-101.LAB) — 22KB
• qttb-20240325_pre.xml (EX-101.PRE) — 14KB
• d811189d8k_htm.xml (XML) — 5KB

Risk Factors

Risk Factors The risks associated with the Company's business and operations and the combined company's business and operations are described in Exhibit 99.2 hereto and are incorporated herein by reference. Financial Information Audited Financial Statements The audited financial statements of the Company as of and for the years ended December 31, 2023 and 2022 and the related notes thereto are set forth in Item 9.01 of this Current Report on Form 8-K and are incorporated herein by reference. Unaudited Pro Forma Condensed Combined Financial Information The unaudited pro forma condensed combined financial information of the Company and Homology as of and for the year ended December 31, 2023 and the related notes thereto are set forth in Item 9.01 of this Current Report on Form 8-K and are incorporated herein by reference.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2023 and 2022 is set forth in Exhibit 99.4 to this Current Report on Form 8-K, and is incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations for Homology for the years ended December 31, 2023 and 2022 are included in Homology's annual report on Form 10-K for the fiscal year ended December 31, 2023 that was filed with the SEC on March 13, 2024, and is incorporated herein by reference. Additional information regarding management's discussion and analysis of the financial condition and results of operations prior to the Merger is included in Homology's definitive proxy statement/prospectus included in the Registration Statement, or the Proxy Statement/Prospectus, in the sections entitled " Homology's Management's Discussion and Analysis of Financial Condition and Results of Operations " beginning on page 352 and " Q32 Management's Discussion and Analysis of Financial Condition and Results of Operations " beginning on page 373, which are incorporated herein by reference.

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table sets forth certain information regarding beneficial ownership of our common stock as of March 25, 2024 and reflects the 1-for-18 reverse stock split of our common stock effected March 25, 2024. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the right to acquire within 60 days of March 25, 2024 the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to them, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. The table lists applicable percentage ownership based on 11,929,528 shares of common stock outstanding as of March 25, 2024. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days, including upon the exercise of stock options and the vesting of restricted stock units. These stock options and restricted stock units shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of our common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the pe

View Full Filing

View this 8-K filing on SEC EDGAR